Ebrahimi, Nasim
Fardi, Elmira
Ghaderi, Hajarossadat
Palizdar, Sahar
Khorram, Roya
Vafadar, Reza
Ghanaatian, Masoud
Rezaei-Tazangi, Fatemeh
Baziyar, Payam
Ahmadi, Amirhossein
Hamblin, Michael R.
Aref, Amir Reza
Funding for this research was provided by:
NIH Blueprint for Neuroscience Research (R01AI050875, R21AI121700)
Article History
Received: 8 November 2022
Revised: 31 January 2023
Accepted: 13 February 2023
First Online: 22 March 2023
Declarations
:
: MRH declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; JOOVV Inc, Minneapolis-St. Paul MN; Sunlighten, Kansas City, MO; Consulting; USHIO Corp, Japan; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany; Klox Asia, Guangzhou, China. Stockholding: Niraxx Light Therapeutics, Inc, Irvine CA; JelikaLite Corp, New York NY. The other authors declare that they have no competing interests.